Daniel Estes, Ph.D.

Dr. Estes joined Frazier Healthcare Partners in 2011 and focuses on investments in both development-stage and commercial-stage pharmaceutical companies. He serves on the boards of Semnur Pharmaceuticals and Outpost Medicine. He has also been involved in Frazier’s investments in Acerta (acquired by AstraZeneca), Tobira (acquired by Allergan), PreCision Dermatology (acquired by Valeant), Sierra Oncology (NASDAQ: SRRA), and others. Prior to joining Frazier, Dr. Estes was a management consultant with McKinsey & Company’s healthcare practice, where he led teams that advised global pharmaceutical and biotechnology companies on R&D strategy and business development strategy.  He received his Ph.D. in biomedical engineering from the University of Michigan, and also holds a B.S. in electrical engineering from Stanford University.